Breaking News Instant updates and real-time market news.

AIMT

Aimmune

08:09
11/28/16
11/28
08:09
11/28/16
08:09

Aimmune announces global enrollment completion of phase 3 AR101 PALISADE trial

Aimmune Therapeutics announced it has completed global enrollment of its Phase 3 PALISADE trial of AR101 for the treatment of peanut allergy, with the total randomized to the trial expected to be approximately 540 patients. AR101 is Aimmune's investigational biologic oral immunotherapy for desensitization of patients with peanut allergy. Aimmune continues to expect topline data from PALISADE in 4Q17, followed by regulatory submissions for marketing approval of AR101 in 2018 in both the U.S. and Europe. The company announced completion of North American enrollment in PALISADE in September, ahead of schedule and above target enrollment. Aimmune also announced ARTEMIS, a new dedicated European clinical trial of AR101 in peanut-allergic children and adolescents. ARTEMIS is designed to expand the data available on the efficacy profile of AR101 by exploring a higher level of protection after a shorter treatment period in a broader group of patients than in PALISADE. The primary efficacy endpoint in this new trial will be tolerating a cumulative amount of 2,043 mg of peanut protein in an exit double-blind, placebo-controlled food challenge after approximately nine months of treatment with AR101. ARTEMIS is a randomized, double-blind, placebo-controlled trial in peanut-allergic children and adolescents ages 4-17. The inclusion criteria for the trial will allow for baseline toleration of a cumulative amount not exceeding 144 mg of peanut protein in an entry DBPCFC. Patients will undergo approximately six months of up-dosing and then three months of maintenance therapy at 300 mg of AR101 per day, followed by an exit DBPCFC. Aimmune expects ARTEMIS to enroll between 120 and 160 patients at multiple sites in Europe, beginning in mid-2017.

  • 29

    Nov

  • 01

    Dec

  • 14

    Dec

AIMT Aimmune

06/28/16
PIPR
06/28/16
NO CHANGE
Target $38
PIPR
Overweight
Piper reiterates Overweight on Aimmune after management meetings
After hosting meetings with management, Piper Jaffray analyst Charles Duncan reiterates an Overweight rating on Aimmune Therapeutics (AIMT) with a $38 price target. The stock closed yesterday down 44c to $11.01 and is down over 40% year-to-date. No matter how the Phase II data is dissected, Aimmune's AR101 appears to produce a higher response rate in about 50% less time than DBV Technologies' (DBVT) Viaskin, Duncan tells investors in a research note. He believes investors may be overlooking future potential drivers of competitive advantage for AR101.
08/23/16
PIPR
08/23/16
NO CHANGE
PIPR
Aimmune data positive, says Piper Jaffray
Piper Jaffray analyst Charles Duncan says that a study of Aimmune's OIT in very young children with peanut allergies indicates that it provides "clinically meaningful protection and perhaps even a disease modifying effect." The analyst says that the drug demonstrated "unexpectedly good" tolerability, and he believes that the data indicates that the drug could be differentiated versus the current standard of care. He keeps a $38 price target and Overweight rating on the stock.
09/21/16
PIPR
09/21/16
NO CHANGE
Target $38
PIPR
Overweight
Aimmune enrollment completion a 'big positive,' says Piper Jaffray
Piper Jaffray analyst Charles Duncan calls Aimmune Therapeutics' announcement yesterday that it completed North American enrollment of 350 patients in its Phase III PALISADE trial of AR101 as a "big positive." The faster than expected timelike "speaks to the unmet need in peanut allergy across the differentiated, broad patient population enrolled in PALISADE, Duncan tells investors in a research note. The analyst reiterates an Overweight rating on the shares with a $38 price target.
09/26/16
JMPS
09/26/16
INITIATION
Target $30
JMPS
Outperform
Aimmune initiated with an Outperform at JMP Securities
JMP Securities analyst Liisa Bayko initiated Aimmune with an Outperform and a $30 price target. The analyst is confident that AR101 Phase 3 data will show meaningful desensitization to peanuts in allergic children and adults and we will be paying close attention to safety and any discontinuations and projects $1.4B in sales by 2028.

TODAY'S FREE FLY STORIES

FEYE

FireEye

$16.98

-0.16 (-0.93%)

, PANW

Palo Alto Networks

$141.75

-1.12 (-0.78%)

21:49
09/20/17
09/20
21:49
09/20/17
21:49
Hot Stocks
SEC discloses hack of Edgar system in 2016 »

Securities and Exchange…Reference Link

FEYE

FireEye

$16.98

-0.16 (-0.93%)

PANW

Palo Alto Networks

$141.75

-1.12 (-0.78%)

QLYS

Qualys

$52.45

0.25 (0.48%)

CHKP

Check Point

$111.27

-1.71 (-1.51%)

PFPT

Proofpoint

$92.19

0.32 (0.35%)

FTNT

Fortinet

$38.24

-0.3 (-0.78%)

SYMC

Symantec

$33.72

-0.44 (-1.29%)

IMPV

Imperva

$44.45

-0.15 (-0.34%)

FFIV

F5 Networks

$116.83

0.07 (0.06%)

CUDA

Barracuda

$24.32

-0.15 (-0.61%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    Sep

  • 22

    Sep

  • 25

    Sep

  • 26

    Sep

  • 27

    Sep

  • 28

    Sep

  • 29

    Sep

  • 05

    Oct

  • 06

    Oct

  • 10

    Oct

  • 18

    Oct

  • 19

    Oct

OMP

Oasis Midstream Partners

20:38
09/20/17
09/20
20:38
09/20/17
20:38
Syndicate
Oasis Midstream Partners 7.5M share IPO priced at $19.00 »

The deal priced at the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    Sep

XLRN

Acceleron

$37.73

-1.24 (-3.18%)

20:37
09/20/17
09/20
20:37
09/20/17
20:37
Syndicate
Acceleron 5.405M share Secondary priced at $37.00 »

JPMorgan, Citi and…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    Sep

IOVA

Iovance Biotherapeutics

$7.15

-1.4 (-16.37%)

19:46
09/20/17
09/20
19:46
09/20/17
19:46
Syndicate
Iovance Biotherapeutics 7.69M share Secondary priced at $6.50 »

The deal priced at $6.50,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Sep

  • 21

    Sep

SAFM

Sanderson Farms

$162.06

1.5 (0.93%)

, CAB

Cabela's

$61.45

0.07 (0.11%)

18:28
09/20/17
09/20
18:28
09/20/17
18:28
Hot Stocks
S&P announces changes to S&P MidCap 400, S&P SmallCap 600 indices »

S&P SmallCap 600…

SAFM

Sanderson Farms

$162.06

1.5 (0.93%)

CAB

Cabela's

$61.45

0.07 (0.11%)

TPRE

Third Point Reinsurance

$14.40

-0.1 (-0.69%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

WDC

Western Digital

$86.37

-3.55 (-3.95%)

, TOSYY

Toshiba, also use TOSBF

$17.08

-0.29 (-1.67%)

18:26
09/20/17
09/20
18:26
09/20/17
18:26
Hot Stocks
Sandisk subsidiaries initiate new arbitration proceedings against Toshiba »

Western Digital (WDC)…

WDC

Western Digital

$86.37

-3.55 (-3.95%)

TOSYY

Toshiba, also use TOSBF

$17.08

-0.29 (-1.67%)

TOSBF

Toshiba, also use TOSYY

$2.87

-0.02 (-0.69%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

NOA

North American Energy

$4.10

-0.05 (-1.20%)

18:26
09/20/17
09/20
18:26
09/20/17
18:26
Hot Stocks
North American Energy awarded two earthworks contracts for $90M »

North American Energy has…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

ISTR

Investar Holding

$23.15

0.15 (0.65%)

18:01
09/20/17
09/20
18:01
09/20/17
18:01
Hot Stocks
Investar Holding raises quarterly dividend to 3c from 2c per share »

The dividend is payable…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

BECN

Beacon Roofing

$47.86

-0.63 (-1.30%)

17:56
09/20/17
09/20
17:56
09/20/17
17:56
Syndicate
Beacon Roofing 6.325M share Secondary priced at $47.50 »

BofA/Merrill, RBC Capital…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    Sep

AMD

AMD

$13.74

0.62 (4.73%)

, AMPH

Amphastar

$15.64

-0.02 (-0.13%)

17:46
09/20/17
09/20
17:46
09/20/17
17:46
Hot Stocks
On The Fly: After Hours Movers »

HIGHER: AMD (AMD), up 6%…

AMD

AMD

$13.74

0.62 (4.73%)

AMPH

Amphastar

$15.64

-0.02 (-0.13%)

GVP

GSE Systems

$2.80

0.05 (1.82%)

MLHR

Herman Miller

DPS

Dr Pepper Snapple

$91.68

-0.12 (-0.13%)

JUNO

Juno Therapeutics

$45.21

1.41 (3.22%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    Sep

  • 28

    Sep

ABMD

Abiomed

$157.42

0.32 (0.20%)

17:36
09/20/17
09/20
17:36
09/20/17
17:36
Hot Stocks
Abiomed receives FDA PMA approval for Impella RP for right heart failure »

Abiomed has received FDA…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

OSK

Oshkosh

$79.69

0.34 (0.43%)

17:35
09/20/17
09/20
17:35
09/20/17
17:35
Hot Stocks
Oshkosh awarded $466.7M government contract modification »

Oshkosh Defense, Oshkosh,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

AET

Aetna

$155.03

-1.01 (-0.65%)

17:32
09/20/17
09/20
17:32
09/20/17
17:32
Hot Stocks
Aetna president Lynch sells $2.5M of company shares »

The president of health…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

APRN

Blue Apron

$5.22

-0.29 (-5.26%)

17:25
09/20/17
09/20
17:25
09/20/17
17:25
Hot Stocks
Blue Apron jumps after meal kit competitor Plated acquired by Albertsons »

Earlier today, food…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

DPS

Dr Pepper Snapple

$91.68

-0.12 (-0.13%)

17:22
09/20/17
09/20
17:22
09/20/17
17:22
Earnings
Dr Pepper Snapple cuts FY17 EPS view to $4.53-$4.63 from $4.56-$4.66 »

FY17 consensus $4.63. In…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

HBI

Hanesbrands

$24.64

-0.07 (-0.28%)

17:22
09/20/17
09/20
17:22
09/20/17
17:22
Downgrade
Hanesbrands rating change at Nomura Instinet »

Hanesbrands downgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

TPRE

Third Point Reinsurance

$14.40

-0.1 (-0.69%)

, SAFM

Sanderson Farms

$162.06

1.5 (0.93%)

17:19
09/20/17
09/20
17:19
09/20/17
17:19
Hot Stocks
Breaking Hot Stocks news story on Third Point Reinsurance, Sanderson Farms »

Third Point Reinsurance…

TPRE

Third Point Reinsurance

$14.40

-0.1 (-0.69%)

SAFM

Sanderson Farms

$162.06

1.5 (0.93%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

SAFM

Sanderson Farms

$162.06

1.5 (0.93%)

, CAB

Cabela's

$61.45

0.07 (0.11%)

17:18
09/20/17
09/20
17:18
09/20/17
17:18
Hot Stocks
Sanderson Farms to replace Cabela's in S&P 400 at open on 9/26 »

Bass Pro Shops is…

SAFM

Sanderson Farms

$162.06

1.5 (0.93%)

CAB

Cabela's

$61.45

0.07 (0.11%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

IPCI

Intellipharmaceutics

17:14
09/20/17
09/20
17:14
09/20/17
17:14
Hot Stocks
Intellipharmaceutics receives Nasdaq non-compliance notice »

Intellipharmaceutics has…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Sep

RWLK

ReWalk Robotics

17:13
09/20/17
09/20
17:13
09/20/17
17:13
Syndicate
Breaking Syndicate news story on ReWalk Robotics »

ReWalk Robotics files to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

ABM

ABM

$39.29

0.23 (0.59%)

17:11
09/20/17
09/20
17:11
09/20/17
17:11
Hot Stocks
Breaking Hot Stocks news story on ABM »

Thomas H. Lee Advisors…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

IVTY

Invuity

$8.35

-0.15 (-1.76%)

17:07
09/20/17
09/20
17:07
09/20/17
17:07
Hot Stocks
Breaking Hot Stocks news story on Invuity »

Discovery Group raises…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Sep

  • 16

    Nov

USG

USG

$31.26

1.84 (6.25%)

, CBPX

Continental Building

$25.60

1.25 (5.13%)

17:04
09/20/17
09/20
17:04
09/20/17
17:04
Hot Stocks
Gypsum stocks jump after peer National Gypsum announces price increase »

Shares of companies…

USG

USG

$31.26

1.84 (6.25%)

CBPX

Continental Building

$25.60

1.25 (5.13%)

EXP

Eagle Materials

$105.07

2.9 (2.84%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Sep

TRHC

Tabula Rasa HealthCare

$25.66

-0.38 (-1.46%)

16:46
09/20/17
09/20
16:46
09/20/17
16:46
Recommendations
Tabula Rasa HealthCare analyst commentary at Piper Jaffray »

Tabula Rasa HealthCare…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Sep

16:40
09/20/17
09/20
16:40
09/20/17
16:40
General news
Fed Leans into Wind on Balance Sheet: »

Fed Leans into Wind on…

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.